 On Monday, August 10, Matinas BioPharma Hldgs AMEX: MTNB will release its latest earnings report. Benzingas outlook for Matinas BioPharma Hldgs is included in the following report.Earnings and Revenue Based on managements projections, Matinas BioPharma Hldgs analysts modeled for EPS of -0.03 per share on sales of 20.00 thousand. In the same quarter last year, Matinas BioPharma Hldgs also reported EPS at -0.03 on sales of 89.81 thousand. If the company were to match the consensus estimate when it reports Monday, earnings would not change. Heres how the companys reported EPS has compared to analyst estimates in the past:Quarter Q1 2020 Q4 2020 Q3 2019 Q2 2019 EPS Estimate -0.03 -0.03 -0.03 -0.03 EPS Actual -0.03 -0.04 -0.03 -0.03 Revenue Estimate 30.00 K 20.00 K 10.00 K 20.00 K Revenue Actual 0 0 0 89.81 K Stock Performance Over the last 52-week period, shares of Matinas BioPharma Hldgs are up 32.91.View more earnings on MTNBLooking at these results, shareholders should be feeling unsatisfied with these results.Dont be surprised to see the stock move on comments made during its conference call. Matinas BioPharma Hldgs is scheduled to hold the call at 16:30:00 ET and can be accessed here: more from Benzinga Earnings Outlook For National Health Investors Integra Lifesciences Earnings Preview Earnings Outlook For KforceC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 